Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats
- 94 Downloads
Cholinergic receptor blockade produces memory deficits in animal models. These deficits can be prevented by 5-HT3 receptor antagonists, such as ondansetron, which increases acetylcholine release. We investigated the effects on cognitive performance of combined treatments of ondansetron with either flumazenil, a GABAA receptor benzodiazepine site antagonist, or tacrine, a cholinesterase inhibitor, which are also able to prevent scopolamine-induced cognitive impairment.
Spatial learning and memory was assessed by studying the effects of single and combined treatments on acquisition and retention of the Morris water maze task in rats.
Scopolamine (0.6 mg/kg) induced significant learning and retention deficits. Both ondansetron (0.1 μg/kg) and tacrine (3 mg/kg) partially prevented the scopolamine-induced learning deficit. A full reversal was only found after the combined treatment of ondansetron with flumazenil (10 mg/kg) and also after tacrine in combination with ondansetron. Likewise, scopolamine-induced retention deficit was fully counteracted by the combined treatment of ondansetron with either flumazenil or tacrine, and only partially by any of the single treatments tested.
The scopolamine-induced impairment of learning and retention in the water maze is fully prevented by ondansetron when given in combination with either flumazenil or tacrine, suggesting that both combined treatments result in a potentiated cholinergic function and may constitute the basis of a new therapy for cognitive disorders.
KeywordsSerotonin GABA Ondansetron Tacrine Flumazenil Morris water maze
Supported in part by a grant from Gobierno de Navarra (Spain). Monica Garcia-Alloza is a fellow from FIS (Instituto de Salud Carlos III, Spain). We thank Mari-Luz Muro for technical help.
- Barnes JM, Barnes NM, Costall B, Naylor MJ, Tyers MB (1989) 5-HT3 receptor mediate inhibition on acetylcholine release in cortical tissue. Nature 338:762–763Google Scholar
- Cassel JC, Jeltsch H (1995) Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 69:1–41Google Scholar
- Costall B, Naylor RJ (1997) Neuropharmacology of 5-HT3 receptors ligands. In: Baumgarten HG, Göthert M (eds) Serotoninergic neurons and 5-HT receptors in the CNS. Springer, Berlin Heidelberg New York, pp 409–438Google Scholar
- Costall B, Domeney AM, Kelly ME, Naylor RJ (1992) Influence of 5-HT on cognitive performance. Adv Biosci 85:147–164Google Scholar
- Dringenberg HC, Laporte PP, Diavolitsis P (2000) Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. NeuroReport 11:3513–3516Google Scholar
- Duka T, Ott H, Rohloff A, Voet B (1996) The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology 123:361–373Google Scholar
- Hindmarch I (1998) Cognition and anxiety: the cognitive effects of anti-anxiety medication. Acta Pschiatr Scand 393:89–94Google Scholar
- Hodges H, Sowinski P, Turner JJ, Fletcher A (1996) A comparision of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology 125:146–161PubMedGoogle Scholar
- Klotz U (1988) Drug interactions and clinical pharmacokinetics of flumazenil. Eur J Anaesthesiol [Suppl] 2:103–108Google Scholar
- Meneses A (1998) Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Rev Neurosci 9:275–289Google Scholar